Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
Truist Securities expressed a positive outlook on Boston Scientific (NYSE:BSX) shares, raising the price target to $120 from $110, while reaffirming a Buy rating. The stock, currently trading near its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback